ContractExclusive Patent and Know-How License Agreement • March 2nd, 2009 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Southampton
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [*], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
RESEARCH COLLABORATION AND COMMERCIALIZATION AGREEMENTResearch Collaboration and Commercialization Agreement • March 2nd, 2009 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • New Jersey
THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of October 20, 2006 (the “Effective Date”), is entered by and between CELLDEX THERAPEUTICS, INC., a New Jersey corporation, with a principal place of business at 222 Cameron Drive, Suite 400, Phillipsburg, New Jersey, NJ 08865, (“Celldex”) and the LUDWIG INSTITUTE FOR CANCER RESEARCH, a Swiss not-for-profit corporation with a registered office at Stadelhoferstrasse 22, 8001 Zurich, Switzerland, and an office at 605 Third Avenue, 33rd Floor, New York, NY 10158 USA, (“Ludwig”).
Vaccine Adjuvant License and Collaboration AgreementVaccine Adjuvant License and Collaboration Agreement • March 2nd, 2009 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • Minnesota
This Agreement is made on the 30th day of May, 2008 (“Effective Date”) by and among 3M COMPANY (“3M”) and 3M INNOVATIVE PROPERTIES COMPANY (“3M IPC”), a wholly-owned subsidiary of 3M, both with a principal address as 3M Center, St. Paul, MN 55144 (collectively “3M”); and Celldex Therapeutics, with a principal address at 222 Cameron Drive Suite 400, Phillipsburg, NJ 08865 (“CELLDEX”).
